Regeneron Pharmaceuticals, Inc. (REGN)
735.20
+0.39
(+0.05%)
USD |
NASDAQ |
Oct 02, 16:00
735.13
-0.07
(-0.01%)
After-Hours: 20:00
Regeneron Pharmaceuticals Profit Margin (Quarterly) : 30.23% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 30.23% |
| March 31, 2026 | 20.17% |
| December 31, 2025 | 21.74% |
| September 30, 2025 | 38.89% |
| June 30, 2025 | 37.86% |
| March 31, 2025 | 26.70% |
| December 31, 2024 | 24.22% |
| September 30, 2024 | 36.03% |
| June 30, 2024 | 40.38% |
| March 31, 2024 | 22.96% |
| December 31, 2023 | 33.77% |
| September 30, 2023 | 29.97% |
| June 30, 2023 | 30.66% |
| March 31, 2023 | 25.86% |
| December 31, 2022 | 35.06% |
| September 30, 2022 | 44.81% |
| June 30, 2022 | 29.82% |
| March 31, 2022 | 32.83% |
| December 31, 2021 | 45.01% |
| September 30, 2021 | 47.27% |
| June 30, 2021 | 60.31% |
| March 31, 2021 | 44.10% |
| December 31, 2020 | 47.43% |
| September 30, 2020 | 36.71% |
| June 30, 2020 | 45.97% |
| Date | Value |
|---|---|
| March 31, 2020 | 34.16% |
| December 31, 2019 | 42.50% |
| September 30, 2019 | 38.40% |
| June 30, 2019 | 12.24% |
| March 31, 2019 | 33.59% |
| December 31, 2018 | 42.56% |
| September 30, 2018 | 35.75% |
| June 30, 2018 | 34.29% |
| March 31, 2018 | 31.62% |
| December 31, 2017 | 10.97% |
| September 30, 2017 | 25.88% |
| June 30, 2017 | 26.38% |
| March 31, 2017 | 18.87% |
| December 31, 2016 | 20.63% |
| September 30, 2016 | 21.70% |
| June 30, 2016 | 16.18% |
| March 31, 2016 | 15.10% |
| December 31, 2015 | 14.12% |
| September 30, 2015 | 18.50% |
| June 30, 2015 | 19.49% |
| March 31, 2015 | 8.74% |
| December 31, 2014 | 13.73% |
| September 30, 2014 | 10.98% |
| June 30, 2014 | 13.93% |
| March 31, 2014 | 10.46% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -134.2% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Amgen, Inc. | 23.59% |
| Incyte Corp. | 34.98% |
| Vertex Pharmaceuticals, Inc. | 32.89% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 13.94% |
| Return on Assets | 10.74% |
| Return on Invested Capital | 12.80% |
| Gross Profit Margin (Quarterly) | 83.68% |
| Operating Margin (Quarterly) | 33.11% |
| Return on Net Operating Assets | 27.85% |